News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

DermTech Announces Addition To Board Of Directors

8/24/2017 6:40:58 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
LA JOLLA, Calif., Aug. 23, 2017 /PRNewswire/ -- DermTech, Inc., the global leader in non-invasive molecular dermatology, is pleased to announce the appointment of Herman "Herm" Rosenman to its Board of Directors. Mr. Rosenman, C.P.A., brings more than 30 years of public company operating and financial experience to DermTech. He received a B.B.A. in finance and accounting from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.

Mr. Rosenman was most recently the Chief Financial Officer at Natera Inc., a leading innovator in prenatal genetic testing, from January 2014 to January 2017. He was previously Senior Vice President of finance and Chief Financial Officer of Gen-Probe Inc., where he was instrumental in its 2002 IPO and 2012 sale to Hologic Inc. for $3.7 billion. Prior to joining Gen-Probe, he was president and chief executive officer of RadNet Management Inc., a large healthcare provider. Before this, he was the chief financial officer of Rexene Corp., a Fortune 1000 company in the petrochemicals industry, where he led its successful $150 million IPO and $500 million debt financing.

John Dobak, M.D., CEO of DermTech commented, "I am extremely pleased to add Herm Rosenman to our Board of Directors. DermTech will benefit greatly from his years of experience and success in genomics molecular testing." Mr. Rosenman commented, "DermTech is one of the most exciting and innovative companies I have seen in my 30 years in the health care industry. I look forward to joining the team and contributing to their success."

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit:

Read at

comments powered by Disqus